Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
344.75
-2.32 (-0.67%)
At close: Jan 23, 2026, 4:00 PM EST
344.69
-0.06 (-0.02%)
After-hours: Jan 23, 2026, 7:31 PM EST
Amgen Revenue
Amgen had revenue of $9.56B in the quarter ending September 30, 2025, with 12.40% growth. This brings the company's revenue in the last twelve months to $35.97B, up 10.56% year-over-year. In the year 2024, Amgen had annual revenue of $33.42B with 18.57% growth.
Revenue (ttm)
$35.97B
Revenue Growth
+10.56%
P/S Ratio
5.15
Revenue / Employee
$1,284,679
Employees
28,000
Market Cap
185.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | 23.36B | -385.00M | -1.62% |
| Dec 31, 2018 | 23.75B | 898.00M | 3.93% |
| Dec 31, 2017 | 22.85B | -142.00M | -0.62% |
| Dec 31, 2016 | 22.99B | 1.33B | 6.14% |
| Dec 31, 2015 | 21.66B | 1.60B | 7.97% |
| Dec 31, 2014 | 20.06B | 1.39B | 7.43% |
| Dec 31, 2013 | 18.68B | 1.41B | 8.17% |
| Dec 31, 2012 | 17.27B | 1.68B | 10.80% |
| Dec 31, 2011 | 15.58B | 529.00M | 3.51% |
| Dec 31, 2010 | 15.05B | 411.00M | 2.81% |
| Dec 31, 2009 | 14.64B | -361.00M | -2.41% |
| Dec 31, 2008 | 15.00B | 232.00M | 1.57% |
| Dec 31, 2007 | 14.77B | 503.00M | 3.53% |
| Dec 31, 2006 | 14.27B | 1.84B | 14.79% |
| Dec 31, 2005 | 12.43B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Merck & Co. | 64.24B |
| Pfizer | 62.79B |
| AbbVie | 59.64B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Sanofi | 53.89B |
| Novo Nordisk | 49.58B |
AMGN News
- 2 days ago - Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential - Seeking Alpha
- 4 days ago - Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access - Business Wire
- 9 days ago - Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing - Barrons
- 10 days ago - Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses - Benzinga
- 11 days ago - Amgen CEO says weight loss drug can address 'patient persistence issue' - CNBC
- 11 days ago - Ro partners with Amgen to study barriers to obesity care, GLP-1 access - Reuters
- 11 days ago - Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - Amgen says MariTide helped trial patients maintain weight loss - Reuters